A b s t r a c t I In nt tr ro od du uc ct ti io on n: : Recent years' studies have revealed a link between the metabolic syndrome and psoriasis. The common elements of pathogenesis of both diseases, primarily associated with severe inflammation, may be responsible for an increased incidence of metabolic syndrome components in psoriasis patients. A Ai im m: : To evaluate the prevalence of selected risk factors for the metabolic syndrome in patients with psoriasis and possible involvement of these factors in the severity of psoriasis. M Ma at te er ri ia al l a an nd d m me et th ho od ds s: : The study included 117 adult psoriatic patients compared with a control group. The severity of psoriasis was evaluated using the PASI and mNAPSI score. Basic laboratory tests were performed. The body mass index (BMI), De Ritis ratio and blood pressure were determined for each patient. R Re es su ul lt ts s: : In the psoriasis group, excess body weight and abnormal values of BMI were significantly more frequent. Body mass index and body weight were significantly higher in patients with the calculated De Ritis ratio than in other subjects. The levels of erythrocyte sedimentation rate and C-reactive protein were significantly higher in the psoriasis group and positively correlated with BMI. Compared with controls, patients with psoriasis had significantly higher values of systolic and diastolic blood pressure, with no correlation with the severity of psoriasis evaluated using the PASI and mNAPSI score. C Co on nc cl lu us si io on ns s: : The results obtained in our study indicate that psoriatic patients appear to be at a higher risk of the metabolic disorders such as hypertension, obesity, liver dysfunction, increased inflammatory parameters than healthy subjects, irrespective of the full manifestation of the metabolic syndrome. We suggest that patients with psoriasis should be routinely screened for the presence of the above-mentioned disorders. K Ke ey y w wo or rd ds s: : psoriasis, metabolic syndrome, De Ritis ratio, C-reactive protein, hypertension.

Objective: In PSO-LONG, long-term proactive management (PAM) of psoriasis with fixed-dose combination calcipotriol 50 mg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) aerosol foam was superior to conventional reactive management. This post-hoc analysis investigated long-term PAM with Cal/BD foam in PSO-LONG patients who could be more susceptible to corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression. Methods: Efficacy and safety of PAM with Cal/BD foam (twice-weekly) versus reactive management (twice-weekly vehicle foam), with once-daily rescue Cal/BD foam for four weeks following relapse, was assessed in the HPA subgroup (n ¼ 66); patients had moderate-to-severe psoriasis (physician global assessment score 3; 10-30% body surface area affected). Primary endpoint was time to first relapse. Results: PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0.49; p ¼ .029), greater proportion of days in remission (17%; p ¼ .001) and reduced rate of relapse (60% reduction; p < .001) than reactive management. Adverse events occurred in 37.5% (PAM) and 47.1% (reactive management) of patients, with no new safety signals. No clinically significant HPA-axis suppression was observed. Conclusion: Efficacy of PAM with Cal/BD foam is maintained in patients with moderate-to-severe psoriasis, with no new safety signals.

Recently, the potential risk of malignant cancer development in psoriatic patients has been highlighted. However, the relationship between the therapeutic schemes in psoriasis and possible neoplastic transformation has not been so far clearly explained. Phototherapy is considered a very effective therapeutic method in psoriasis, however, the pathogenesis of some malignancies may be associated with the exposure to UV radiation. p16 protein belongs to the defense mechanisms that protect cells from damage and mutagenic factors, such as UV radiation. In recent years, the altered expression of the p16 protein in the diseases not related to malignant transformation, including psoriasis, has been observed. These new observations suggest participation of the p16 protein in the mechanisms of psoriatic plaque formation.

Abstract:Recently, the potential risk of malignant cancer development in psoriatic patients has been highlighted. However, the relationship between the therapeutic schemes in psoriasis and possible neoplastic transformation has not been so far clearly explained. Phototherapy is considered a very effective therapeutic method in psoriasis, however, the pathogenesis of some malignancies may be associated with the exposure to UV radiation. p16 protein belongs to the defense mechanisms that protect cells from damage and mutagenic factors, such as UV radiation. In recent years, the altered expression of the p16 protein in the diseases not related to malignant transformation, including psoriasis, has been observed. These new observations suggest participation of the p16 protein in the mechanisms of psoriatic plaque formation.

No abstract